Potent antitubulin tumor cell cytotoxins based on 3-aroyl indazoles

Journal of Medicinal Chemistry

Volumn 50, Issue 5, 2007, Pages 1001-1006

  Duan, Jian Xin ^a   Cai, Xiaohong ^a   Meng, Fanying ^a   Lan, Leslie ^a   Hart, Charles ^a   Matteucci, Mark ^a  

^a Threshold Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLENE; COLCHICINE; COMBRETASTATIN A4; CYTOTOXIN; DAUNORUBICIN; INDAZOLE DERIVATIVE; PACLITAXEL; TUBULIN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING COMPETITION; CANCER CELL CULTURE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MICROTUBULE ASSEMBLY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ACETYLENE; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CATTLE; CELL LINE, TUMOR; COLCHICINE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDAZOLES; RADIOLIGAND ASSAY; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS;

EID: 33847777267     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061348t     Document Type: Article

References (15)

1. Bacher, G.; Beckers, T.; Emig, P.; Kienner, T.; Kutscher, B.; Nickel, B. New small-molecule tubulin inhibitors. Pure Appl. Chem. 2001, 73 (9), 1459-1464.
2. Nam, N.-H. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr. Med. Chem. 2003, 10, 1697-7222.
3. (a) Pettit, G. R.; Temple, C., Jr.; Narayanan.; L.; Varma, R.; Simpson, M. J.; Boyd, M. R.; Rener, G. A.; Bansal, N. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. 1995, 10, 299-309.
4. (b) Pettit, G. R.; Rhodes, M. R. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des. 1998, 13 (3), 183-191.
5. Liou, J.-P.; Chang, C.-W.; Song, S.; Yang, Y.-N.; Yeh, C.-F.; Tseng, H.-T.; Lo, Y.-K.; Chang, Y.-L.; Chang, C.-M.; Hsieh, H.-P. Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. J. Med. Chem. 2002, 45, 2556-2567, and references cited there.
6. Liou, J.-P.; Chang, Y.-L.; Kuo, F.-M.; Chang, C.-W.; Tseng, H.-H.; Wang, C.-C.; Yang, Y.-N.; Chang, J.-Y.; Lee, S.-J.; Hsieh, H.-P. Concise synthesis and structure-activity relationships of cobrestatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents. J. Med. Chem. 2004, 47, 4247-4257.
7. Provot, O.; Giraud, A.; Peyrat, J.; Alami, M.; Brion, J. Synthetic approach to enyne and enediyne analogues of anticancer agents. Tetrahedron Lett. 2005, 49, 8547-8550.
8. Idiya, G. F.; Nataliya, A. Z. On the cyclization of ortho-alkynylbenzene diazonium salts. Tetrahedron Lett. 2005, 29, 5453-5455.
9. Beauregard, D. A.; Pedley, R. B.; Hill, S. A.; Brindle, K. M. Differential sensitivity of two adenocarcinoma xenografts to the antivascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed. 2002, 15, 99-105.
10. Atalay, C.; Deliloglu, G. I.; Irkkan, C.; Gunduz, U. Multidrug resistance in locally advanced breast cancer. Tumor Biol. 2006, 27 (6), 309-318.
11. Harker, W. G.; Sikic, B. I. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res. 1985, 45, 4091-4096.
12. Kochevar, J. Blockage of autonomous growth of ACHN cells by anti-renal cell carcinoma monoclonal antibody 5F4. Cancer Res. 1990, 50, 2968-2972.
13. Hipfner, D. R.; Gauldie, S. D.; Deeley, R. G.; Cole, S. P. Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res. 1994, 54, 5788-5792.
14. Hamel, E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin. Cell Biochem. Biophys. 2003, 38, 1-21.
15. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca., S.; Genazzani, A. A. Medicinal chemistry of combrestatin A4: present and future directions. J. Med. Chem. 2006, 49 (11), 3033-3044.